NF2 and neoplasm: Recently, in our hospital, a clinical trial using a VEGFRs peptide vaccine was also conducted in patients with progressive neurofibromatosis type 2 (NF2)-derived schwannomas, showing hearing improvement and tumor volume reduction [15].